Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?

被引:43
作者
Drouet, Ludovic [1 ,2 ]
Sollier, Claire Bal Dit [1 ,2 ]
Steiner, Thorsten [3 ,4 ]
Purrucker, Jan [3 ]
机构
[1] Hop Lariboisiere, Paris, France
[2] Univ Paris 07, Paris, France
[3] Univ Heidelberg Hosp, Dept Neurol, Heidelberg, Germany
[4] Klinikum Frankfurt Hochst, Dept Neurol, Frankfurt, Germany
关键词
Non-vitamin K antagonist oral anticoagulants; administration and dosage; therapeutic use; coagulation testing; stroke; prevention; ISCHEMIC-STROKE PATIENTS; COAGULATION ASSAYS; BLEEDING COMPLICATIONS; LABORATORY MEASUREMENT; EMERGENCY MANAGEMENT; DABIGATRAN; WARFARIN; RIVAROXABAN; APIXABAN; EDOXABAN;
D O I
10.1177/1747493016659671
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Although the need for an emergency intervention may merit laboratory measurement of non-vitamin K antagonist oral anticoagulant (NOAC) concentration or anticoagulant activity, NOACs are not supposed to require routine monitoring due to their stable pharmacological profiles compared with warfarin. Aims To examine situations where NOAC measurement may be useful and to provide information about methodologies available to measure NOAC-related anticoagulation activity. Summary of review The routine coagulation tests, including prothrombin time, thrombin time, activated partial thromboplastin time, and international normalized ratio, have variable sensitivities to NOACs. Tests have been developed for use with specific NOACs, e.g. diluted thrombin time or chromogenic factor Xa assays. In emergency situations, such as severe bleeding, stroke, or a requirement for urgent surgery or procedures, there may be a need to assess anticoagulant activity to guide clinical decision making. In cases where neutralization of the anticoagulant effect is warranted, specific reversal agents are likely to become invaluable medical tools. Evidence to date suggests that dosing decisions for NOACs based on clinical features (e.g. age or renal function) can help optimize the benefit-risk balance without assessment of anticoagulant activity in non-emergency routine situations. Conclusions Regular monitoring of NOAC levels does not provide benefits and cannot be recommended at present. In some specific circumstances, e.g. severe bleeding, before urgent surgery, or before thrombolysis, measurement may be beneficial to assess whether a patient is actively anticoagulated. The availability of NOAC-specific reversal agents may change management practices in emergencies.
引用
收藏
页码:748 / 758
页数:11
相关论文
共 61 条
[1]   Guidelines for the early management of adults with ischemic stroke - A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups [J].
Adams, Harold P., Jr. ;
del Zoppo, Gregory ;
Alberts, Mark J. ;
Bhatt, Deepak L. ;
Brass, Lawrence ;
Furlan, Anthony ;
Grubb, Robert L. ;
Higashida, Randall T. ;
Jauch, Edward C. ;
Kidwell, Chelsea ;
Lyden, Patrick D. ;
Morgenstern, Lewis B. ;
Qureshi, Adnan I. ;
Rosenwasser, Robert H. ;
Scott, Phillip A. ;
Wijdicks, Eelco F. M. .
STROKE, 2007, 38 (05) :1655-1711
[2]   Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Ageno, Walter ;
Gallus, Alexander S. ;
Wittkowsky, Ann ;
Crowther, Mark ;
Hylek, Elaine M. ;
Palareti, Gualtiero .
CHEST, 2012, 141 (02) :E44S-E88S
[3]   Oral Apixaban for the Treatment of Acute Venous Thromboembolism [J].
Agnelli, Giancarlo ;
Buller, Harry R. ;
Cohen, Alexander ;
Curto, Madelyn ;
Gallus, Alexander S. ;
Johnson, Margot ;
Masiukiewicz, Urszula ;
Pak, Raphael ;
Thompson, John ;
Raskob, Gary E. ;
Weitz, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09) :799-808
[4]  
[Anonymous], 2015, EUR HEART J
[5]   Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma [J].
Antovic, Jovan P. ;
Skeppholm, Mika ;
Eintrei, Jaak ;
Boija, Elisabet Eriksson ;
Soderblom, Lisbeth ;
Norberg, Eva-Marie ;
Onelov, Liselotte ;
Ronquist-Nii, Yuko ;
Pohanka, Anton ;
Beck, Olof ;
Hjemdahl, Paul ;
Malmstrom, Rickard E. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (11) :1875-1881
[6]   Coagulation assays [J].
Bates, SM ;
Weitz, JI .
CIRCULATION, 2005, 112 (04) :E53-E60
[7]   Targeted Anti-Anticoagulants [J].
Bauer, Kenneth A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (06) :569-571
[8]   Pros and cons of new oral anticoagulants [J].
Bauer, Kenneth A. .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, :464-470
[9]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[10]   Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor [J].
Becker, Richard C. ;
Yang, Hongqiu ;
Barrett, Yuchen ;
Mohan, Puneet ;
Wang, Jessie ;
Wallentin, Lars ;
Alexander, John H. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) :183-187